 Somatostatin
"Somatostatin" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A 14-amino acid peptide named for its ability to inhibit pituitary GROWTH HORMONE release, also called somatotropin release-inhibiting factor. It is expressed in the central and peripheral nervous systems, the gut, and other organs. SRIF can also inhibit the release of THYROID-STIMULATING HORMONE; PROLACTIN; INSULIN; and GLUCAGON besides acting as a neurotransmitter and neuromodulator. In a number of species including humans, there is an additional form of somatostatin, SRIF-28 with a 14-amino acid extension at the N-terminal.
| Descriptor ID |
D013004
|
| MeSH Number(s) |
D06.472.699.327.700.875 D06.472.699.587.780 D12.644.400.400.700.875 D12.644.548.365.700.875 D12.644.548.586.780 D12.776.641.650.405.700.875
|
| Concept/Terms |
Somatostatin- Somatostatin
- Somatostatin, Cyclic
- Somatostatin-14
- Somatostatin 14
- SRIH-14
- Somatotropin Release-Inhibiting Factor
- Somatotropin Release Inhibiting Factor
- Somatotropin Release-Inhibiting Hormone
- Somatotropin Release Inhibiting Hormone
- Cyclic Somatostatin
|
Below are MeSH descriptors whose meaning is more general than "Somatostatin".
Below are MeSH descriptors whose meaning is more specific than "Somatostatin".
This graph shows the total number of publications written about "Somatostatin" by people in this website by year, and whether "Somatostatin" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1980 | 0 | 1 | 1 | | 1981 | 4 | 1 | 5 | | 1982 | 2 | 0 | 2 | | 1983 | 2 | 0 | 2 | | 1984 | 0 | 1 | 1 | | 1985 | 0 | 2 | 2 | | 1986 | 1 | 2 | 3 | | 1987 | 0 | 2 | 2 | | 1988 | 4 | 1 | 5 | | 1992 | 0 | 1 | 1 | | 1993 | 3 | 4 | 7 | | 1994 | 1 | 1 | 2 | | 1995 | 2 | 1 | 3 | | 1996 | 2 | 5 | 7 | | 1997 | 1 | 0 | 1 | | 1998 | 0 | 4 | 4 | | 2002 | 0 | 1 | 1 | | 2005 | 0 | 1 | 1 | | 2009 | 1 | 1 | 2 | | 2018 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Somatostatin" by people in Profiles.
-
Fowler JL, Lee SS, Wesner ZC, Olehnik SK, Kron SJ, Hara M. Three-Dimensional Analysis of the Human Pancreas. Endocrinology. 2018 03 01; 159(3):1393-1400.
-
Kim A, Miller K, Jo J, Kilimnik G, Wojcik P, Hara M. Islet architecture: A comparative study. Islets. 2009 Sep-Oct; 1(2):129-36.
-
Mukhopadhyay A, McGuire T, Peng CY, Kessler JA. Differential effects of BMP signaling on parvalbumin and somatostatin interneuron differentiation. Development. 2009 Aug; 136(15):2633-42.
-
Monte O, Zyngier S, Kimura ET, Bianco AC. [Dopaminergic and somatostatinergic pathways decrease serum thyrotropin in rats bearing the 256-Walker mammary carcinoma]. Arq Bras Endocrinol Metabol. 2005 Apr; 49(2):253-64.
-
Alarcon C, Wicksteed B, Prentki M, Corkey BE, Rhodes CJ. Succinate is a preferential metabolic stimulus-coupling signal for glucose-induced proinsulin biosynthesis translation. Diabetes. 2002 Aug; 51(8):2496-504.
-
Charlton MR, Nair KS. Role of hyperglucagonemia in catabolism associated with type 1 diabetes: effects on leucine metabolism and the resting metabolic rate. Diabetes. 1998 Nov; 47(11):1748-56.
-
Lipman NS, Wardrip CL, Yuan CS, Coventry S, Bunte RM, Li X. Familial megacecum and colon in the rat: a new model of gastrointestinal neuromuscular dysfunction. Lab Anim Sci. 1998 Jun; 48(3):243-52.
-
Bollheimer LC, Skelly RH, Chester MW, McGarry JD, Rhodes CJ. Chronic exposure to free fatty acid reduces pancreatic beta cell insulin content by increasing basal insulin secretion that is not compensated for by a corresponding increase in proinsulin biosynthesis translation. J Clin Invest. 1998 Mar 01; 101(5):1094-101.
-
Pick A, Clark J, Kubstrup C, Levisetti M, Pugh W, Bonner-Weir S, Polonsky KS. Role of apoptosis in failure of beta-cell mass compensation for insulin resistance and beta-cell defects in the male Zucker diabetic fatty rat. Diabetes. 1998 Mar; 47(3):358-64.
-
Ren J, Bell G, Coy DH, Brunicardi FC. Activation of human somatostatin receptor type 2 causes inhibition of cell growth in transfected HEK293 but not in transfected CHO cells. J Surg Res. 1997 Jul 15; 71(1):13-8.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|